FDA warned BioDrive that its Evolv GLP-1 Biomimetic dietary supplement is adulterated over the new dietary ingredient EV1-Peptide and safety concerns.
What happened
The letter does not describe an inspection; FDA evaluated the product labeling and two new dietary ingredient notifications (safety submissions) that BioDrive sent to FDA. FDA found that the label declares Saccharomyces cerevisiae S288C EV-1 Peptide as a dietary ingredient, that it is a new dietary ingredient, and that there is inadequate information to reasonably assure it does not present a significant or unreasonable risk. FDA said BioDrive marketed Evolv GLP-1 Biomimetic despite FDA's safety objections.
What FDA found
The supplement contains EV1-Peptide, a new dietary ingredient for which FDA says there is inadequate information to reasonably assure it does not present a significant or unreasonable risk of illness or injury.
section 402(f)(1)(B) of the Act [21 U.S.C. § 342(f)(1)(B)]EV1-Peptide is a new dietary ingredient because FDA has no information showing it was marketed in the U.S. before October 15, 1994.
section 413(d) of the Act [21 U.S.C. § 350b(d)]BioDrive introduced or delivered the adulterated supplement into interstate commerce, which the Act prohibits.
section 301(a) of the Act [21 U.S.C. § 331(a)]
What FDA wants
FDA asks BioDrive to notify it in writing within 15 working days of the specific steps taken to address the violations, with an explanation of each step and related documents. If corrective actions cannot be completed in that time, BioDrive must state why and give a completion date.
Who should pay attention
- retailers that sell BioDrive's supplements
- brands that use new dietary ingredients
- consumers taking GLP-1 mimetic dietary supplements
This is a summary. Read the original letter on fda.gov.